USSTOCK.TODAY
Market Closed
Log in Sign up

Autolus Therapeutics reports Q3 revenue growth and raises AUCATZYL guidance

Earnings Whispers · ·by G4L

AUTL
AUTL Autolus Therapeutics plc ADR
$1.24 -6.44%
View chart & analysis →
  1. 1Autolus Therapeutics recorded $41.24 million in AUCATZYL net product sales for Q3, representing a 94.6% year-over-year growth in AUCATZYL net product sales.
  2. 2Autolus Therapeutics raised its 2026 AUCATZYL guidance to more than $150 million.
  3. 3The FDA approved RMAT designation for obe-cel for lupus and lupus nephritis.

So what's the key point?

Autolus Therapeutics' AUCATZYL sales reached $41.24 million. The company raised its 2026 AUCATZYL sales forecast to more than $150 million.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Autolus Therapeutics reports 95% Q3 revenue growth and raises guidance The Motley Fool +1 · 22h agoAviat Networks records Q1 loss due to declining profitability despite record orders Earnings Whispers · 2h agoBrainsWay Misses Third Quarter Earnings and Revenue Estimates Earnings Whispers · 2h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news